control human dermal fibroblasts  (Fisher Scientific)

Journal: Journal of Biomedical Science

Article Title: Modeling CLN3 Batten disease in astrocytes reveals alterations in mitochondria homeostasis, fatty acid metabolism and oxidative stress response

doi: 10.1186/s12929-026-01253-y

Figure Lengend Snippet: Generation and characterization of iPSC-derived astrocytes. A Schematic overview of astrocyte differentiation from patient-derived iPSCs. Key compounds used to drive differentiation toward a mature astrocyte phenotype are indicated: LIF (leukemia inhibitory factor), CHIR99021, SB431542, CoE, FGF2 (fibroblast growth factor 2), EGF (epidermal growth factor), and CNTF (ciliary neurotrophic factor). B qPCR analysis of astrocyte-specific markers (ALDHL1, GLAST, S100b, GFAP, Vimentin) in iPSC-derived cells. Expression of MAP2 (neuron marker) and OLIG2 (oligodendrocyte marker) was assessed to evaluate cell population purity. C Phase-contrast images and immunocytochemical validation of astrocyte marker expression. Vimentin and GFAP (green), S100β (red), and DAPI-stained nuclei (blue) are shown. D Quantification of CLN3 protein levels in control and CLN3 patient-derived iPSC and astrocytes via targeted mass spectrometry

Article Snippet: Healthy control fibroblast lines (two cell lines) were obtained from ATCC (cat. number PCS-201—012) and the Coriell Institute (cat. number AG05836).

Techniques: Derivative Assay, Expressing, Marker, Biomarker Discovery, Staining, Control, Mass Spectrometry

Journal: bioRxiv

Article Title: Phosphorylated ubiquitin is a secondary messenger and an epigenetic mark mediating mitochondria to nucleus signaling

doi: 10.64898/2026.04.24.719390

Figure Lengend Snippet: A - Human fibroblasts were treated with mitochondrial toxins (CCCP, 50µM; valinomycin, 1µM; oligomycin 10µM + antimycin, 4µM) or DMSO for 0, 4, 8 and 24 hrs. Top: Representative immunofluorescence images from 24 hr timepoint showing distribution of pS65Ub (green). Bottom: Quantification shows mean +/- SEM pS65Ub intensity in cytoplasm, nucleus and nucleus:cytoplasm relative to 0 hrs timepoint (separated with vertical dashed line) from 1 experiment with 3 technical repeats. The horizontal line shows the 0hr-normalized baseline. B - Fibroblasts were treated with valinomycin (1µM, 24 hrs) before pS65Ub (green) was visualized by immunofluorescence using multiple specific antibodies. Nuclei (blue) are annotated with green asterisks. C - Confocal Z-stack max projections showing human induced dopaminergic neurons treated with oligomycin + antimycin (OA, 1µM, 24 hrs) and stained for pS65Ub (green), the dopaminergic neuron marker tyrosine hydroxylase (TH; magneta), MAP2 (white) and Hoechst (blue). Dashed boxes indicate areas magnified in pS65Ub channel inset and dashed circles delineate nuclei. D - Wild type (WT) and PINK1 knockout (KO) HeLa cells were treated with CCCP (20µM, 4 hrs) as indicated, then subcellular fractionations were analysed by Western blot. E - HeLa were treated with CCCP (20µM, 4 hrs) or OA (1µM, 24 hrs) before immunoblot analysis of whole-cell lysates using two pS65Ub antibodies. F - HeLa, HEK293T, NCI-H226, murine melanoma, murine PDAC or human skin fibroblast cells were treated with OA, then pS65Ub levels were assessed by Western blot. G - NGN2-induced iPSC-derived neurons were treated with OA (1µM, 6 or 24 hrs) before subcellular fractionation and Western blot analysis. H - HeLa were treated with CCCP (20µM, 4 hrs), rotenone (Rot - 20µM, 20 hrs), paraquat (P3/P6 - 3/6mM, 20 hrs) or CCCP+i (PINK1 inhibitor/PRT062607, 2.5µM, 4 hrs). Quantifications show mean +/-SEM from three independent repeats, *** p<0.0001 (CCCP+i treatment performed twice only so excluded from quantification). I - HeLa cells were treated with 10µM Gamitrinib-TPP (GTPP) for 0, 3 or 20hrs before analysis of whole-cell lysates by Western blot. Red asterisks mark the pS65Ub-histone band. Scale bars 10µm (50µM for panel D). Dashed lines in panels E and F indicate where identical samples were run on separate blots.

Article Snippet: Control primary fibroblasts (#106-05A) were from Cell Applications, Inc., PINK1 (Q456X/Q456X, #sc1028) and Parkin (Ex4-7 del / c.203_204 del AG, #sc1064) mutant fibroblasts are available from the NINDS stem cell repository.

Techniques: Immunofluorescence, Staining, Marker, Knock-Out, Western Blot, Derivative Assay, Fractionation

Journal: bioRxiv

Article Title: Phosphorylated ubiquitin is a secondary messenger and an epigenetic mark mediating mitochondria to nucleus signaling

doi: 10.64898/2026.04.24.719390

Figure Lengend Snippet: A - Schematic depiction of subcellular fraction experiment performed in . Detergent buffers used for fractionation are given in italics. CIB and MIB buffers are from Cell Fractionation Kit (Cell Signaling Technologies, #9038), while HNTE was made in house. B - Cells were treated with OA (1µM, 18 hrs), MG132 (20µM, 4 hrs) or DMSO before subcellular fractionation and Western blotting. Protein subcellular localizations are annotated (IMM = inner mitochondrial membrane, OMM = outer mitochondrial membrane) and arrows indicate both full length and cleaved PINK1 bands. For the pS65Ub blot, identical samples were analyzed on a separate gel (separated by dashed lines). C - PINK1-HA was transiently expressed in HeLa cells before treatment with OA, MG132 or DMSO as before. The distributions of pS65Ub (green), HA (red) and DNA (blue) were assessed by immunofluorescence. Magnified regions of interest are indicated by dashed boxes. Red dashed lines indicate regions captured by intensity profile (performed in the red/HA channel), graphed below. D - WT or PINK1 KO HeLa were transiently transfected with empty vector (EV), PINK1-FKBP (P) or FIS1-FRB (F) in combinations indicated before 18 hrs treatment with OA (1μM) or rapalog (500nM). A dashed line reveals where identical samples were analyzed on a separate gel. E - Schematic depiction of experiments performed in Extended Data Figures 4F, G. F - WT or PINK1 KO HeLa cells were transiently transfected with EV, PINK1 WT, PINK1-NES or PINK1-NLS before treatment with CCCP and Western blot analysis. Two plasmid amounts were used for transfection to achieve high and low relative PINK1 expression, captured by high and low exposures (HiExp/LoExp respectively). G - PINK1-myc tagged with NES/NLS signals were transiently expressed in HeLa cells before treatment with CCCP (20µM, 4 hrs) or MG132 (20µM, 4 hrs). Cells were fixed and stained for myc (green), pS65Ub (blue, grayscale in the far right column) or mitochondrial marker HSP60 (red). Nuclear exclusion (NES) and sequestration (NLS) is observed after MG132 treatment. H - Quantification of nuclear vs cytoplasmic pS65Ub signal density (arbitrary units/µm 2 ) in healthy control, PRKN (left) and PINK1 (right) mutant iPSC-derived dopaminergic neurons after treatment with CCCP (10µM, 6 hrs). The horizontal line shows the signal on DMSO-treatment, considered background due to negligible PINK1 activation/pS65Ub levels. Mean +/- SEM from three independent cell lines per genotype. I - iPSC-derived dopaminergic neurons from PD patients with mutations in PINK1 were treated with CCCP (10µM, 6 hrs). Dashed boxes annotate the area magnified in the inset and dashed circles show nuclear borders. Inset zoom in of pS65Ub channel. See for Control and PRKN mutant conditions. J - Skin fibroblasts from PINK1 / PRKN mutant PD donors and healthy controls were treated with valinomycin (1µM, 8 hours) before Western blot analysis. Maximal Parkin activity (revealed by MFN2 ubiquitination, see band shift) and PINK1 activity (substrate pS65Ubiquitination) is only detected in WT cells treated with valinomycin. K - Fibroblasts were treated with valinomycin (1µM, 0-24 hrs) before fixation and immunofluorescence analysis of pS65Ub (green, grayscale in the left hand column), TOM20 (orange) and DNA (blue). Nuclear:cytoplasmic pS65Ub signal intensity from three experiments was quantified, with mean +/-SEM, 2-way ANOVA shown. Red asterisks identify the pS65Ub-histone band *p<0.05, **p<0.01, ***p<0.001. Scale bars 10µm.

Article Snippet: Control primary fibroblasts (#106-05A) were from Cell Applications, Inc., PINK1 (Q456X/Q456X, #sc1028) and Parkin (Ex4-7 del / c.203_204 del AG, #sc1064) mutant fibroblasts are available from the NINDS stem cell repository.

Techniques: Fractionation, Cell Fractionation, Western Blot, Membrane, Immunofluorescence, Transfection, Plasmid Preparation, Expressing, Staining, Marker, Control, Mutagenesis, Derivative Assay, Activation Assay, Activity Assay, Ubiquitin Proteomics, Electrophoretic Mobility Shift Assay

Journal: Antioxidants

Article Title: Bioenergetic Signatures of DLD Deficiency: Dissecting PDHc- and α-KGDHc-Linked Defects

doi: 10.3390/antiox15010019

Figure Lengend Snippet: Mitochondrial respiration is impaired in fibroblasts derived from patients with DLD deficiency. Mitochondrial oxygen consumption was assessed in controls (Ctrl1 and Ctrl2) and patient (Pt1–Pt6) fibroblasts using high-resolution respirometry (Oroboros O2k). ( A ) Routine respiration; ( B ) maximal respiration calculated as the difference between FCCP-stimulated and α-chaconine–permeabilized rates; ( C ) complex I-linked respiration (NADH-linked respiration, N-pathway), calculated as the difference between ADP and α-chaconine; ( D ) complex II-linked respiration (NS-pathway) calculated as the difference between respiration after rotenone and α-chaconine addition; ( E ) effect of complex I inhibition, calculated as the difference between FCCP-stimulated and rotenone-inhibited respiration; and ( F ) complex I/complex II respiration ratio (complex I-linked activity divided by complex II-linked activity). Each open circle represents an independent experimental run (N = 4–8 repeats per sample). All data were normalized to cell number. Statistical analysis was performed using the Mann–Whitney U test. * p < 0.05 vs. Ctrl1; numerical p values (0.05 < p < 0.1) are indicated on the plots. Abbreviations: Ctrl, control; Pt, patient.

Article Snippet: Dermal fibroblast primary cell lines from six genetically confirmed patients with DLD deficiency were obtained from the Pediatric Metabolic Disease Unit, Sheba Medical Center (IRB# SMC-21-8644, Figure 1, Table 1, and ), as well as two control cell lines: a control human dermal fibroblast cell line was purchased from ATCC (PCS-201-012; Ctrl 1, Manassas, VA, USA), and a primary cell line from a 39-year-old healthy male (Ctrl 2).

Techniques: Derivative Assay, Inhibition, Activity Assay, MANN-WHITNEY, Control

Journal: Experimental Biology and Medicine

Article Title: N-acetyl-L-cysteine improves mitochondrial and oxidative defects in the acadian variant of fanconi syndrome

doi: 10.3389/ebm.2025.10448

Figure Lengend Snippet: Fibroblasts derived from Acadian variant of Fanconi syndrome (AVFS) patients have mitochondrial deficits and oxidative damage. (A) Immunoblotting and quantification of mitochondrial proteins in fibroblasts derived from control or AVFS patients showing lower levels of NDUFAF6 and the complex I subunit NDUFA9 but not of SDHA, UQRCRC2 and TOM20. (B) The enzymatic activity of complex I is decreased in AVFS fibroblasts (n = 9). (C) Fluorescence of the mitochondrial membrane potential-dependent TMRM is decreased in AVFS fibroblasts (n = 6). (D) Oxygen consumption rates (OCR) at different respiratory states indicating lower mitochondrial metabolism in AVFS fibroblasts (n = 3-4). (E–G) Levels of (E) 8-hydroxy-2′-deoxyguanosine (8-OHdG), (F) malondialdehyde (MDA) and (G) carbonyl, which indicate oxidative damage on DNA, lipid and protein, respectively, are increased in AVFS fibroblasts (n = 3). Data are presented as mean +- SEM. Data with different letters are statistically different, as measured by one way ANOVA followed by post-hoc Tukey test.

Article Snippet: Control fibroblasts were obtained from ATCC (ref. PCS-201-012).

Techniques: Derivative Assay, Variant Assay, Western Blot, Control, Activity Assay, Fluorescence, Membrane

Journal: Experimental Biology and Medicine

Article Title: N-acetyl-L-cysteine improves mitochondrial and oxidative defects in the acadian variant of fanconi syndrome

doi: 10.3389/ebm.2025.10448

Figure Lengend Snippet: Treatment with the antioxidant N-Acetyl-L-cysteine (NAC) reverses oxidative damage in fibroblasts derived from Acadian variant of Fanconi syndrome (AVFS) patients. (A) TMRM fluorescence in control fibroblasts do not change after treatment with NAC (1 mM, 5 days, n = 9). (B) MDA levels in control fibroblasts do not change after treatment with NAC (n = 9). (C) Representative immunoblotting (n = 3) of NDUFAF6 in control and AVFS fibroblasts with vehicle or NAC, showing that NAC does not rescue levels of NDUFAF6. (D) The enzymatic activity of complex I is partly rescued in AVFS fibroblasts upon treatment with NAC (n = 12). (E) TMRM fluorescence is partly rescued in AVFS fibroblasts treated with NAC (n = 6-7). (F) Oxygen consumption rates (OCR) at different respiratory states are partly rescued upon treatment with NAC (n = 3) (G–I) Levels of (G) 8-hydroxy-2′-deoxyguanosine (8-OHdG), (H) malondialdehyde (MDA) and (I) carbonyl, which indicate that oxidative damage on DNA, lipid and protein, respectively, are partly rescued in AVFS fibroblasts treated with NAC (n = 3). Data are presented as mean +- SEM. Data with different letters are statistically different, as measured by one way ANOVA followed by post-hoc Tukey test.

Article Snippet: Control fibroblasts were obtained from ATCC (ref. PCS-201-012).

Techniques: Derivative Assay, Variant Assay, Fluorescence, Control, Western Blot, Activity Assay

Journal: JCI Insight

Article Title: A toxic gain-of-function variant in MAPK8IP3 provides insights into JIP3 cellular roles

doi: 10.1172/jci.insight.187199

Figure Lengend Snippet: ( A ) Cells (2,000 cells/well) were seeded in 96 wells for 3 days. Cell proliferation was measured by MTT assay (left). Apoptosis induction was measured by caspase-3/7 activity (right). All of results were normalized to healthy patient-derived fibroblasts (control cells, 2,936). n = 5, * P < 0.05, ** P < 0.01. ( B ) JIP3, JIP3, p-JNK, and total JNK proteins levels were measured by Western blot and normalized to GAPDH. ( C ) Trafficking of Cy3-transferrin along with microtubules in cells was detected with a Keyence microscope. Microtubules were stained by anti-tubulin antibody. mTOCs were marked with white dashed lines. Zoomed-in views were provided for the regions within the frames, with white arrows indicating representative colocalization sites. Scale bar: 50 μm; original magnification, ×63. ( D ) Cell imaging of either patient-derived fibroblasts or control fibroblasts incubated with 1 μM Cy3-transferrin for different time points. Colocalization of Cy3-transferrin and Rab7 (late endosome [LE] marker) was observed with a Keyence microscope. Zoomed-in views were provided for the regions within the frames, with white arrows indicating representative colocalization sites. Scale bar: 50 μm. ( E ) Cell imaging of either YFP-TLR4–transfected patient fibroblasts or healthy control fibroblasts incubated with 10 μg/mL LPS for different time points. Colocalization of activated YFP-TLR4 and Rab7 observed with a Keyence BZ-X800 microscope. Nuclei were marked with white dashed lines. Scale bar: 50 μm. ( F ) Cell imaging of lysosomes (LAMP1, a lysosome marker) either in patient-derived fibroblasts or healthy control fibroblasts observed by a Keyence microscope. Average distance between lysosome cluster to the center of nucleus in cells was measured by BZ-X800 analyzer software with the 3D model analysis function. Scale bar: 10 μm. Control cells, n = 85; patient cells, n =109. Unpaired t test.

Article Snippet: Three human dermal control fibroblasts (GM02936, GM03529 and GM03440) were purchased from Coriell Institute for Medical Research and cultured in DMEM with 10% FBS.

Techniques: MTT Assay, Activity Assay, Derivative Assay, Control, Western Blot, Microscopy, Staining, Imaging, Incubation, Marker, Transfection, Software

Journal: JCI Insight

Article Title: A toxic gain-of-function variant in MAPK8IP3 provides insights into JIP3 cellular roles

doi: 10.1172/jci.insight.187199

Figure Lengend Snippet: ( A ) Dopamine receptor 1 and 2 (D1 and D2) and p-AKT proteins levels in fibroblasts measured by Western blot. GAPDH was used as a loading control. Either healthy fibroblasts or patient fibroblasts were seeded in 96 wells (10,000 cells/well) and treated with 1 μM ( B ) D1-selective agonist SKF 81297 and ( C ) D2-selective agonist ropinirole for different time points. cAMP levels were measured with a cAMP-Glo Assay (Promega). Data were normalized to untreated control (UTC) of cells at time 0. n = 3. Either healthy individual–derived fibroblasts or patient-derived fibroblasts were seeded in 96 wells (8,000 cells/well) and treated by different concentrations of ( D ) D1-selective agonist SKF 81297 and ( E ) D2-selective agonist ropinirole for 30 minutes. cAMP levels were measured by cAMP-Glo Assay (Promega). Data were normalized to UTC of cells. n = 3. ( F ) Fibroblasts were treated with 1 μM D2-selective antagonist domperidone (Dom) for 5 minutes before addition of 1 μM D1-selective agonist SKF 81297 (SKF) for 30 minutes. Data were normalized to UTC of cells. n = 3. * P < 0.05. ( G ) Fibroblasts were treated with different concentrations of D2-selective antagonist domperidone (Dom) for 30 minutes. cAMP levels were measured by cAMP-Glo Assay (Promega). Data were normalized to UTC of cells. n = 3. ( H ) Fibroblasts were treated with 1 μM β1-AR–selective antagonist bisoprolol, β2-AR–selective antagonist ICH118551, and D1-selective antagonist SCH23390 for 30 minutes. cAMP levels were measured by cAMP-Glo Assay (Promega). Data were normalized to UTC of cells. n = 3. * P < 0.05, ** P < 0.01.

Article Snippet: Three human dermal control fibroblasts (GM02936, GM03529 and GM03440) were purchased from Coriell Institute for Medical Research and cultured in DMEM with 10% FBS.

Techniques: Western Blot, Control, Glo Assay, Derivative Assay

Journal: JCI Insight

Article Title: A toxic gain-of-function variant in MAPK8IP3 provides insights into JIP3 cellular roles

doi: 10.1172/jci.insight.187199

Figure Lengend Snippet: Healthy individual–derived (control) fibroblasts from GM03440 and patient-derived fibroblasts (5,000 cells/well) were electroporated with different concentrations of non-allele-selective ASO3 targeting MAPK8IP3 (JIP3) and incubated in 96 wells with normal culture medium for different time points for different experiments. Scrabble PS-ASO 676630 (5 μM) was used as a control ASO. ( A ) After 72-hour incubation, cell proliferations were measured by MTT assay and normalized to UTC of control cells. n = 3, * P < 0.05, ** P < 0.01. ( B ) After 48-hour incubation, RNA was extracted by GITC assay, and MT-MAPK8IP3 mRNA levels were measured using q-PCR. Data were normalized to UTC of control cells. n = 3, ** P < 0.01. ( C ) WT MAPK8IP3 mRNA levels were measured using q-PCR. Data were normalized to UTC of control cells. n = 3, ** P < 0.01. ( D ) SPAG9 (JIP4) mRNA levels were measured using q-PCR. Data were normalized to UTC of control cells. n = 3, ** P < 0.01. ( E ) Cell proteins were harvested after 72-hour incubation of ASOs with different concentrations. JIP3, JIP4, p-JNK, and total JNK were measured by Western blot. GAPDH was used as a loading control. ( F ) 10 μM non-allele-selective ASO3 was used to treat mutations in patient iPSC neurons for 72 hours, and then 1 μM D1 agonist (SKF 81297) was added to each test group with different incubation time points. cAMP levels were measured by cAMP-Glo Assay (Promega). Data were normalized to UTC of cells. n = 3, * P < 0.05. ( G ) After 48-hour ASO treatment, cell imaging of either patient fibroblasts or healthy control fibroblasts incubated with 1 μM Cy3-transferrin for different time points. Colocalization of Cy3-transferrin and Rab7 (late endosome [LE] marker) was observed with a Keyence BZ-X800 microscope. Scale bar: 20 μm.

Article Snippet: Three human dermal control fibroblasts (GM02936, GM03529 and GM03440) were purchased from Coriell Institute for Medical Research and cultured in DMEM with 10% FBS.

Techniques: Derivative Assay, Control, Incubation, MTT Assay, Western Blot, Glo Assay, Imaging, Marker, Microscopy

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: The DNase TREX1 is a substrate of the intramembrane protease SPP with implications for disease pathogenesis

doi: 10.1007/s00018-025-05645-5

Figure Lengend Snippet: SPP-dependent destabilization of TREX1 in AGS patients with homozygous T303P mutation. A Dermal fibroblasts from patients carrying the TREX1 303P mutation as well as two independent commercially obtained control fibroblast cell lines were monitored for their TREX1 levels by Western Blotting. B TREX1 mRNA abundance was quantified in the same cell lines by qPCR. Mean mRNA levels were normalized to those of control #1. N = 2, n = 3(patient #2), n = 4 (rest). One-Way ANOVA with Tukey’s post hoc test. ** p ≤ 0.01, *** p ≤ 0.001. C Patient fibroblasts were treated with 1 µM inhibitor X (InX) or DMSO as control for 24 h. TREX1 protein levels were finally compared to those from WT control lines by Western Blotting. D PBMCs were isolated from the two patients carrying the TREX1 T303P mutation as well as their mother (heterozygous carrier) or a non-related healthy volunteer. Cells were subsequently treated with DMSO or 1 µM inhibitor X (InX) for 24 h prior to cell lysis. Finally, cellular TREX1 levels were evaluated by Western Blotting

Article Snippet: Control human dermal adult fibroblasts were purchased from either ATCC (PCS-201-012) or Thermo Fisher Scientific (C0135C).

Techniques: Mutagenesis, Control, Western Blot, Isolation, Lysis